Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Nootropic+1 more
Sigma-1 receptor agonistketamine, dextromethorphan, PCP +2 moreketamine, dextromethorphan, PCP, nitrous oxide, MXE show less
Memantine
Memantine (3,5-dimethyladamantan-1-amine) is a synthetic dissociative of the adamantane class. It is a close structural relative of amantadine, with two extra methyl groups that increase potency and receptor selectivity. It blocks glutamate receptors in the brain, dampening excessive neuronal signaling and producing the cognitive disconnection characteristic of dissociatives.[1]
Memantine (3,5-dimethyladamantan-1-amine) is a synthetic dissociative of the adamantane class. A close structural relative of amantadine, it is distinguished by greater potency and receptor selectivity. Memantine is an NMDA receptor antagonist, producing its effects by blocking the channel pore to preferentially attenuate pathological glutamate signaling.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Nootropic+1 more
Sigma-1 receptor agonistketamine, dextromethorphan, PCP +2 moreketamine, dextromethorphan, PCP, nitrous oxide, MXE show less
Synthesized by Eli Lilly in the mid-1960s as a potential blood-sugar-lowering drug, memantine failed as an antidiabetic before Merz identified its brain effects and launched it in Germany in 1989 for dementia.[2] The FDA approved it in October 2003 as Namenda for moderate-to-severe Alzheimer's disease.[3] It is now among the most widely prescribed neurological drugs in the United States, with active clinical research into OCD, PTSD, and chemotherapy-related cognitive decline.[4][5]
Subjective effects include cognitive disconnection, emotional suppression, perceptual flattening, mild dissociation, and a clear-headed detachment from bodily awareness. The experience is defined by its extraordinary duration — a slow-building, multiday cognitive detachment closer to a sustained mental haze than the acute dissociative plunge of ketamine.[6] Prolonged depersonalization, confusion, and a persistent fear that normal cognition will not return are characteristic unwanted effects.
Memantine produces low to negligible dependence, and its safety at approved doses matches placebo in clinical trials.[7] The main danger at higher doses is pharmacokinetic: the 60–80 hour half-life locks users into multiday experiences, and urine alkalinizers — antacids, baking soda — can increase drug exposure by up to 80%,[8] making dose control unpredictable. Clinical data are robust at therapeutic doses but nonexistent above 20 mg — the entire recreational range falls within an uncharacterized evidence gap.
History[edit]
Discovery
Memantine was synthesized by Eli Lilly between 1963 and 1966 as a potential blood-sugar-lowering drug.[9] It failed as an antidiabetic, and its brain effects went unrecognized for over a decade until the German company Merz identified them. Clinical trials began in 1986,[9] and Merz launched it in Germany in 1989 under the names Akatinol and Axura — years before its mechanism was fully understood.[2][1]
Clinical significance
In the late 1990s, researchers characterized memantine as an NMDA glutamate receptor antagonist.[10] Lipton and colleagues explained why it worked where similar drugs had failed: its fast, shallow binding blocked pathological signaling while sparing the brief channel openings needed for normal brain function.[11][12] This understanding — the "uncompetitive/fast off-rate" model — became foundational to how this class of drugs is designed.[1]
Regulatory approval and modern use
The European Medicines Agency approved memantine for moderate-to-severe Alzheimer's disease in 2002,[2] and the FDA followed in October 2003 as Namenda.[3] The pivotal trial showed cognitive and functional benefits at 20 mg/day over 28 weeks.[7] By 2022, over 114 branded formulations had been registered globally,[9] including the fixed-dose combination Namzaric (memantine + donepezil).[13]
The name memantine derives from its chemistry: methyl + amine + adamantane. The compound occupies an unusual cultural position — a mass-market prescription drug with a quiet secondary life as one of the least recreational dissociatives.
Chemistry[edit]
Memantine belongs to the adamantane chemical family — a rigid, cage-like carbon structure formed from three fused rings. Its closest relative is amantadine (the unsubstituted parent compound, used for influenza and Parkinson's disease). Two extra methyl groups on the cage increase memantine's potency and modify how it interacts with glutamate receptors.[10]
Its molecular formula is C₁₂H₂₁N (molecular weight 179.30 g/mol), with no chirality centers — no mirror-image forms exist.[14] The amine group carries a positive charge at body pH, enabling it to enter and block the glutamate receptor channel.[14] Memantine hydrochloride is a white crystalline powder.[9]
Pharmacology[edit]
Mechanism of action
Memantine blocks glutamate receptors in the brain by entering the receptor's channel pore only after it has been opened.[11][3] It selectively targets pathological overactivation — the sustained low-level glutamate flood seen in neurodegeneration — while leaving brief normal channel openings mostly intact.[12][1] This selectivity is why memantine is clinically tolerable where other glutamate blockers cause serious neurological adverse effects.[15][16]
Secondary targets
Beyond glutamate receptors, memantine also blocks serotonin receptors and nicotinic acetylcholine receptors at clinically relevant concentrations.[8][17] A 2025 study identified an additional action on calcium-permeable receptors through an entirely different mechanism.[18]
Pharmacokinetics
Memantine is absorbed almost completely after swallowing and is barely processed by the liver — about 48% exits the body unchanged in urine.[8] Its half-life is 60–80 hours, meaning one dose continues acting for days. Anything that makes urine more alkaline — antacids, baking soda, some kidney conditions — slows clearance by roughly 80%,[8] substantially increasing drug exposure.
Neuroscience[edit]
Cortical processing
Memantine selectively reduces feedback processing in the brain — the loops by which higher cortical regions elaborate and amplify incoming signals.[19] This differs from blocking basic sensory input: it dampens the brain's capacity to attend to and interpret complex stimuli.[20] Direct brain recording confirmed that memantine reduces how strongly the brain responds to unexpected stimuli, consistent with NMDA inhibition.[21]
Excitotoxicity and neuroprotection
Memantine's therapeutic rationale rests on the excitotoxicity model: in neurodegeneration, chronically elevated glutamate overstimulates receptors, floods neurons with calcium, and triggers cell death. Memantine's fast, reversible binding dampens this pathological flood while still allowing the brief channel openings needed for learning and memory.[11][1] Studies of brain tissue from treated Alzheimer's patients suggest chronic use may partially restore the balance between excitatory and inhibitory signaling that neurodegeneration disrupts.[22]
- Why does memantine lack the rapid antidepressant effect seen with ketamine, despite both blocking NMDA receptors? Whether the answer lies in binding behavior, pharmacokinetics, or an unidentified mechanism remains unclear.
- Does the recently discovered action on calcium-permeable receptors[18] contribute to neuroprotection at therapeutic doses in the human brain?
- What is the dose-response curve for dissociative effects in healthy people? No controlled studies have examined memantine above therapeutic doses — the transition to dissociative effects is documented only in community reports.
Subjective Effects[edit]
At supratherapeutic doses, memantine produces a dissociative state that is primarily cognitive rather than perceptual. Onset builds gradually over two to three hours. The dominant quality is a clear-headed disconnection from emotional reactivity and bodily awareness — without the immersive visual distortion or euphoric rush of faster-acting dissociatives.
Compared to ketamine or dextromethorphan, memantine dissociation is consistently described as more lucid but less rewarding.[6] The multiday duration and slow onset make it the least acute — and least recreational — NMDA antagonist in common use.
Synthesized by Eli Lilly in the mid-1960s as a candidate antidiabetic, memantine's CNS activity was later identified by Merz and the compound launched in Germany in 1989 for dementia.[2] FDA approval followed in October 2003 under the trade name Namenda for moderate-to-severe Alzheimer's disease.[3] It is now among the most widely prescribed neurological drugs in the United States, with active clinical investigation spanning OCD, PTSD, autism, opioid use disorder, and chemotherapy-related cognitive decline.[4][5]
Subjective effects include cognitive disconnection, perceptual flattening, emotional suppression, and mild dissociation. The experience is defined by its extraordinary duration and clear-headed character — a slow-building, multiday cognitive detachment closer to a sustained nootropic shift than the acute dissociative plunge of ketamine.[6] Prolonged depersonalization, confusion, and a persistent sense that normal cognition will not return are characteristic unsought effects.
Memantine produces low to negligible dependence, and its therapeutic safety profile is excellent — adverse event rates at approved doses match placebo.[7] The primary risk at supratherapeutic doses is pharmacokinetic: the 60–80 hour half-life locks users into multiday experiences, urinary pH shifts can increase drug exposure by up to 80%,[8] and the sole documented massive overdose (2,000 mg) required plasmapheresis despite full recovery.[9] Clinical data are robust at therapeutic doses but nonexistent above 20 mg — the entire recreational dose range falls within an uncharacterized safety gap.
History[edit]
Discovery
Memantine was first synthesized and patented by Eli Lilly between 1963 and 1966 as a potential blood-sugar-lowering agent.[10] The compound failed as an antidiabetic, and its brain activity went unrecognized for over a decade until the German pharmaceutical company Merz identified its central nervous system effects. Clinical trials began in 1986,[10] and Merz launched memantine in Germany in 1989 under the trade names Akatinol and Axura — years before its NMDA mechanism was fully understood.[2][1]
Clinical significance
The mechanistic breakthrough came in the late 1990s when Danysz, Parsons, and colleagues characterized memantine as an NMDA receptor antagonist.[11] Lipton's group then explained why memantine was clinically tolerable where other NMDA blockers had failed: its low affinity, fast offset kinetics, and partial untrapping allowed it to block pathological signaling while sparing normal synaptic transmission.[12][13] This distinction — the "uncompetitive/fast off-rate" (UFO) drug concept — became foundational to NMDA receptor pharmacology.[1]
Regulatory approval and modern use
The European Medicines Agency approved memantine for moderate-to-severe Alzheimer's disease in 2002,[2] and the US FDA followed in October 2003 with the brand name Namenda.[3] The pivotal trial demonstrated cognitive and functional benefits at 20 mg/day over 28 weeks.[7] In 2014, Namzaric — a fixed-dose combination of extended-release memantine and donepezil — received FDA approval,[14] and by 2022 over 114 branded formulations had been registered globally.[10]
The name memantine derives from its systematic chemistry: methyl + amine + adamantane. The compound occupies an unusual cultural position — a mass-market prescription drug with a quiet secondary life as one of the least recreational dissociatives.
Chemistry[edit]
Structural class
Memantine belongs to the adamantane chemical class — a family of polycyclic cage hydrocarbons built on a diamondoid carbon scaffold. The parent compound adamantane forms a rigid, symmetrical cage of ten carbon atoms arranged in three fused cyclohexane rings. Memantine is a 3,5-dimethyl-substituted 1-aminoadamantane: two methyl groups at bridgehead positions and a primary amine define its pharmacological identity.
The adamantane scaffold is shared with amantadine (1-aminoadamantane), the unsubstituted parent amine used for influenza and parkinsonism. Memantine's additional methyl groups increase lipophilicity and modify how it interacts with the NMDA channel, conferring greater potency and selectivity as a channel blocker.[11]
Molecular identity
| Molecular formula | C₁₂H₂₁N |
| Molecular weight | 179.30 g/mol |
The molecule consists of the tricyclic adamantane cage bearing a primary amine (–NH₂) at the C-1 bridgehead and methyl groups at C-3 and C-5.[15] The amine carries a positive charge at physiological pH, enabling voltage-dependent block of the NMDA receptor's cation-permeable channel pore.
Stereochemistry
Memantine possesses no chiral centers and is achiral. The adamantane cage is symmetrical about multiple planes, and the bridgehead substitution pattern preserves this symmetry.[15] No stereoisomers exist.
Physical properties
Memantine hydrochloride presents as a white crystalline powder. The free base dissolves in organic solvents including ethanol, petroleum ether, and chloroform, and is sparingly soluble in water.[10]
Pharmacology[edit]
Mechanism of action
Memantine is a moderate-affinity, uncompetitive, voltage-dependent open-channel blocker of NMDA glutamate receptors.[12][3] It binds within the ion channel pore — at a site overlapping the magnesium binding site — only after the channel has been opened by glutamate. This "use-dependent" mechanism is the foundation of its clinical tolerability.
Under normal conditions, NMDA channels open briefly during synaptic signaling and memantine does not accumulate. Under pathological conditions — such as the sustained, low-level glutamate elevation seen in neurodegenerative disease — channels remain open long enough for memantine to enter and reduce excessive calcium influx.[12][13] This selective blockade of pathological over physiological signaling was formalized as the "uncompetitive/fast off-rate" (UFO) drug concept.[1]
Memantine also partially "untraps" from the closed channel (~20% escape rate), unlike high-affinity blockers such as MK-801 and phencyclidine that remain fully trapped.[16][17]
Secondary targets
Beyond NMDA receptors, memantine blocks serotonin 5-HT₃ receptors at clinically relevant concentrations, which may contribute to antiemetic effects.[8] It also antagonizes nicotinic acetylcholine receptors.[8][18]
A 2025 study revealed that memantine inhibits calcium-permeable AMPA receptors through a mechanism entirely distinct from its NMDA channel block.[19] This previously unknown action may be relevant to neuroprotection in conditions where these receptors contribute to excitotoxic damage.
Memantine shows no significant activity at GABA, benzodiazepine, dopamine, adrenergic, histamine, or glycine receptors.[8]
Pharmacokinetics
Memantine is absorbed nearly completely after oral administration, with bioavailability approaching 100%.[8] Peak blood levels occur 3–7 hours after an immediate-release dose. The half-life is 60–80 hours — among the longest of any NMDA antagonist — meaning a single dose continues to exert effects for days.
The drug undergoes minimal liver metabolism; CYP450 enzymes play no significant role in its breakdown.[8] About 48% is excreted unchanged in urine, and clearance depends heavily on urinary pH. Alkaline urine reduces clearance by approximately 80%, substantially increasing blood levels and prolonging effects.[8] This makes anything that alkalinizes urine — antacids, sodium bicarbonate, certain kidney conditions — a significant variable in how long and how intensely memantine acts.
Food does not meaningfully affect absorption. Severe kidney impairment roughly doubles both blood levels and half-life, requiring dose adjustment.
Neuroscience[edit]
Cortical processing
Memantine selectively modulates recurrent (feedback) cortical processing while leaving feedforward pathways intact. Controlled studies in healthy volunteers showed that memantine enhanced the brain's ability to process complex stimuli that rely on feedback loops — such as perceiving illusory contours — but only when those stimuli were consciously attended.[20] Follow-up work confirmed this effect targets NMDA-dependent recurrent amplification specifically, rather than attention or expectation in general.[21]
Direct measurement via MEG confirmed that memantine increases NMDA receptor inhibition in the living human brain, as reflected by reduced mismatch responses to unexpected auditory stimuli.[22]
Excitotoxicity and neuroprotection
Memantine's clinical rationale emerges from the excitotoxicity model: in neurodegenerative disease, chronically elevated glutamate overstimulates NMDA receptors, flooding neurons with calcium and triggering cell death. Memantine's fast-binding, fast-releasing kinetics allow it to dampen this pathological flood while still permitting the brief NMDA channel openings required for learning and memory.[12][1]
Proteomic analysis of brain tissue from treated Alzheimer's patients found that chronic memantine use triggers compensatory remodeling of both excitatory and inhibitory synaptic pathways,[23] suggesting the drug may partially restore the excitatory-inhibitory balance disrupted in neurodegeneration.
- Why does memantine lack the rapid antidepressant effect seen with ketamine, despite both blocking NMDA receptors? Whether the answer lies in trapping behavior, pharmacokinetics, or an unidentified mechanistic difference remains unclear.
- Does the recently discovered AMPA blockade[19] contribute to memantine's neuroprotective effects at therapeutic concentrations in the human brain?
- What is the dose-response curve for dissociative effects in healthy people? No controlled studies have examined memantine above therapeutic doses — the transition from clinical to dissociative effects is documented only in uncontrolled community reports.
Subjective Effects[edit]
At supratherapeutic doses, memantine produces a dissociative state that is qualitatively unlike an acute ketamine experience. The onset is gradual — building over two to three hours — and the core experience is cognitive rather than perceptual: a clear-headed disconnection from emotional reactivity and bodily awareness, without the immersive visual distortion or euphoric rush of faster-acting NMDA antagonists. Higher doses deepen the dissociation but the ceiling remains moderate, and the experience scales with urinary pH as much as with dose itself.
Compared to Ketamine or dextromethorphan, memantine dissociation is consistently described as more lucid but less rewarding — closer to a long-duration cognitive modifier than a recreational dissociative.[6] The multiday commitment required at effective doses, combined with the slow onset and moderate intensity, positions memantine as the least recreational NMDA antagonist in common use.
Effect Grid
At 70–110 mg, a clear dissociative state establishes itself. Bodily dissociation and cognitive disconnection are prominent — a felt separation between mind and body that distinguishes this from lighter doses. Derealization and depersonalization emerge reliably. Visual perception shifts: visual haze, mild drifting, depth perception distortion. Auditory distortion and suppression are common. Memory suppression becomes noticeable, and thought deceleration is pronounced.
Physical effects include moderate dizziness, motor control impairment, vestibular distortion, and pain suppression. Nausea occurs in a minority. Stimulation may paradoxically coexist with cognitive slowing. Constipation is possible.
The experience lasts 18–24+ hours at full intensity, with cognitive residue extending 1–2 additional days. Sleep is frequently disrupted for 12–24 hours. Functional impairment persists well beyond subjective resolution — plan for 48+ hours of limited capacity.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sensory deprivation · Vestibular distortion · Auditory distortion · Auditory misinterpretation · Touch suppression · Visual acuity suppression · Visual haze / noise · Dreaming enhancement · Tinnitus · Internal hallucinations · Visual processing suppression · Auditory hallucinations · External hallucinations
Touch suppression · Visual acuity suppression · Visual haze / noise · Dreaming enhancement · Tinnitus · Internal hallucinations · Visual processing suppression · Auditory hallucinations · External hallucinations
Body high · Body schema distortion · Nystagmus (eye wobbles) · Pain suppression · Physical fatigue · Bodily heaviness · Bodily lightness · Headache · Muscle relaxation · Restlessness · Spontaneous body sensations · Constipation · Dry mouth · Insomnia · Pupil dilation · Stimulation · Tingling / electric sensations · Vomiting · Abnormal heartbeat · Trembling · Bodily dissociation · Tactile hallucination
Pain suppression · Physical fatigue · Bodily heaviness · Bodily lightness · Headache · Muscle relaxation · Restlessness · Spontaneous body sensations · Constipation · Dry mouth · Insomnia · Pupil dilation · Stimulation · Tingling / electric sensations · Vomiting · Trembling · Bodily dissociation · Tactile hallucination
Information processing suppression · Memory suppression · Thought disorganization · Analysis suppression · Cognitive fatigue · Memory fragmentation · Thought deceleration · Cognitive dysphoria · Cognitive euphoria · Language suppression · Suggestibility enhancement · Thought loops · Amnesia · Delirium · Delusions
Analysis suppression · Cognitive fatigue · Memory fragmentation · Thought deceleration · Cognitive dysphoria · Cognitive euphoria · Language suppression · Thought loops · Amnesia · Delirium · Delusions
Irritability · Anxiety suppression · Emotional lability
Social disconnection · Disinhibition · Compulsive behavior reduction · Cognitive disconnection · Boundary dissolution · Ego dissolution
Boundary dissolution · Ego dissolution
Timeline
Gradual awareness of altered state. Subtle cognitive slowing and a faint sense of mental cushioning emerge. Very slow build relative to other dissociatives — consistent with oral Tmax of 3–7 hours.
Progressive dissociative deepening. Body sensation changes, emerging bodily lightness and mild derealization. Perceptual shifts begin — faint visual haze, auditory changes.
Maximum dissociative intensity. Cognitive disconnection, bodily dissociation, and perceptual distortions at their strongest. Memory suppression and analysis suppression are prominent.
Sustained dissociative state with gradual modulation. Effects remain strong but stable — the long half-life produces an extended plateau uncommon among NMDA antagonists. Cognitive function begins slow recovery.
Slow tapering of dissociative effects over many hours. Cognitive function gradually returns. Motor coordination improves but remains subtly impaired.
Residual cognitive alteration, mild dissociative quality, and possible fatigue driven by the 60–80 hour elimination half-life. Subtle perceptual and cognitive effects may persist for days.
⚠ Do not drive or operate heavy machinery for at least 48 hours after use — memantine's long half-life means residual impairment may persist for days.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- Negligible
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- ketamine · dextromethorphan · PCP
Toxicity
Therapeutic dose safety
At approved doses (5–20 mg/day), adverse event rates match placebo.[7][23] Common side effects include dizziness, headache, confusion, diarrhea, constipation, and sedation.[8] Rare post-marketing reports include seizures, severe skin reactions, and cardiac events.[8]
Overdose
safety citation needed The exact toxic dose in humans has not been established. The only published overdose case involved 2,000 mg — roughly 100 times the standard daily dose.[24] The person lost consciousness, developed seizures and a rapid heart rate, and required blood-filtering treatment (plasmapheresis) before making a full recovery.
No antidote exists. Standard treatment includes benzodiazepines for seizures and plasmapheresis for severe cases.[24]
Supratherapeutic dose gap
safety citation needed No controlled human safety data exist above 20 mg. The entire recreational dose range falls within this evidence gap — between the therapeutic ceiling and the single documented massive overdose.
Psychological risks
At therapeutic doses, hallucinations, confusion, and aggressive behavior are documented side effects.[8] At higher doses, the primary psychological risk is duration: dissociative states can last one to three days, and users describe fearing that normal thinking will not return.[6]
Tolerance & Dependence
Tolerance to therapeutic effects has not been observed in trials lasting up to 28 weeks.[7] Memantine has low to negligible dependence potential — its slow onset and multiday duration act as intrinsic deterrents to compulsive use.[6] No withdrawal has been documented, and cross-tolerance with other dissociatives is plausible but unconfirmed.
Drug Interactions
Pharmacokinetic
The most significant interaction is with urinary alkalinizers — antacids, sodium bicarbonate, and carbonic anhydrase inhibitors. These reduce memantine's kidney clearance by approximately 80%, potentially converting a safe dose into a dangerous one.[8] Urinary acidifiers (ammonium chloride) have the opposite effect, increasing clearance and reducing the drug's effects. Because memantine barely enters the liver, CYP-based drug interactions are negligible.[8][25]
Pharmacodynamic
Combining memantine with other NMDA blockers — ketamine, dextromethorphan, amantadine, nitrous-oxide — additively increases the risk of confusion, dissociation, and psychosis.[8]
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are pharmacodynamically complementary — the combination is clinically approved but may increase side effect rates.[13] Some enhancement of L-DOPA effects is possible through glutamate–dopamine circuit interaction.[10][1]
Contraindications
7 knownAllergy to memantine is an absolute contraindication.[8] Severe kidney impairment roughly doubles blood levels and half-life — use requires dose reduction and careful monitoring. Other NMDA antagonists increase neuropsychiatric risk and require caution.[8]
Conditions producing alkaline urine — kidney tubular acidosis, severe urinary infections, chronic antacid use — reduce clearance by ~80% and can convert a tolerable dose into a dangerous one.[8] Seizure disorders warrant caution — seizures are documented in overdose and listed as a rare side effect.[24][8]
Harm Reduction[edit]
Forms & Identification
Memantine circulates only as pharmaceutical tablets, capsules, and oral solution. The key risk is not adulteration but dose verification: tablets from different manufacturers come in different strengths (5 mg, 10 mg, 14 mg, 21 mg, 28 mg). Confirm the exact strength marked on the tablet or packaging before use.
Because memantine is a legal prescription drug, reagent testing is less relevant than with unregulated substances. The primary source of unpredictability is pharmacokinetic — urinary pH, kidney function, and individual variation produce wide differences in how intensely and how long the drug acts.
Guidelines
- Start low. Near-complete bioavailability and multiday duration mean dosing errors compound over days, not hours. Begin well below the intended target.
- Allow full onset time. Peak effects take 3–7 hours. Do not redose before at least 8 hours have passed — stacking doses with a 60–80 hour half-life causes unpredictable accumulation.
- Avoid urinary alkalinizers. Antacids, sodium bicarbonate, and alkaline diets reduce clearance by up to 80%. Avoid these before or during use.
- Clear the schedule. Block at minimum 48 hours with no driving, heavy machinery, or responsibilities requiring full cognitive function.
- Hydrate and eat normally. The multiday timeline makes sustained self-care essential.
- Do not use with impaired kidney function. Reduced clearance roughly doubles blood levels and extends the already long duration.
Set & Setting
Memantine's defining practical challenge is duration. At supratherapeutic doses, effects persist for one to three days — a multiday commitment, not an evening experience. Planning must account for obligations, driving, and cognitive demands across the entire window.
A familiar environment with access to food, water, and sleep space is essential. The clear-headed character of memantine dissociation can create a false sense of normalcy — cognitive impairment may be deeper than it feels. A sober companion who understands the timeline is strongly recommended for first experiences.
Aftercare & integration. The multiday duration means the boundary between "experience" and "aftercare" is blurred. Residual cognitive blunting and emotional flatness may persist for two to four days after peak effects resolve.
During this period, prioritize sleep, regular meals, and low-demand activities. Avoid significant decisions until baseline cognition clearly returns. Journaling helps separate drug-state insights from residual dissociative thinking. If depersonalization or a sense of unreality persists beyond one week, consult a healthcare provider.
Recovery & Support
Memantine dependence is rare, but any pattern of escalating recreational use warrants honest self-assessment. If use is driven by a desire to escape emotional pain or cognitive distress, professional support addresses the underlying need more effectively than repeated dissociative experiences.
Resources for dissociative-related concerns include SAMHSA's National Helpline (1-800-662-4357), local addiction services, and online harm reduction communities. If memantine was obtained via prescription diversion, discussing this with a prescriber reduces long-term risk.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Seizures or convulsions
- Unresponsiveness or loss of consciousness
- Severe confusion progressing to inability to communicate
- Rapid heart rate with chest pain or difficulty breathing
- Sustained high blood pressure (throbbing headache, visual disturbances)
Immediate steps:
- Call emergency services if any of the above signs are present.
- Place an unconscious person in the recovery position.
- Do not induce vomiting.
- Do not attempt to "walk off" seizures — protect the head, clear the area, time the seizure.
- Keep the person calm and in a quiet environment if conscious but severely confused.
What to tell the dispatcher: name the substance (memantine), the amount taken, when it was taken, and current symptoms. Note the extremely long half-life (60–80 hours) — effects will not resolve quickly. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific antidote exists. Hospital treatment may include benzodiazepines for seizures and plasmapheresis for severe overdose.
Legal Status[edit]
Memantine is a prescription-only pharmaceutical approved for moderate-to-severe Alzheimer's disease in all major jurisdictions. It is not classified as a controlled substance under any national drug scheduling framework.[6]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Prescription drug (not scheduled DEA I–V) | FDA-approved October 2003 (NDA 21-627, Namenda). Off-label prescribing legal. 145th most prescribed drug in 2023 (>3 million prescriptions)[3] |
| European Union | Prescription-only medicine | EMA-approved since 2002 for moderate-to-severe AD. Not scheduled as a controlled substance in any EU member state[2] |
| United Kingdom | Prescription-only medicine (POM) | Not scheduled under the Misuse of Drugs Act 1971. Available on NHS for Alzheimer's diseasecitation needed |
| Canada | Prescription-only | Licensed for moderate-to-severe AD. Not a controlled substance. Provincial reimbursement variescitation needed |
| Australia | Schedule 4 (Prescription Only Medicine) | TGA-listed. Not scheduled as a controlled drugcitation needed |
Memantine is not detected by standard immunoassay drug screening panels. Identification requires gas chromatography–mass spectrometry (GC-MS) or liquid chromatography–tandem mass spectrometry (LC-MS/MS).citation needed
Legal status is subject to change and varies by jurisdiction. This information is not legal advice.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- Negligible
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- ketamine · dextromethorphan · PCP
Toxicity
Therapeutic dose safety
At approved doses (5–20 mg/day), memantine demonstrates an excellent safety profile. In the pivotal 28-week trial, adverse event rates and discontinuation rates were no higher with memantine than with placebo.[7] The Cochrane systematic review confirmed this favorable tolerability across multiple trials.[24]
Common side effects at therapeutic doses include dizziness, headache, confusion, diarrhea, constipation, fatigue, and sedation.[8] Rare post-marketing reports include seizures, severe skin reactions (Stevens-Johnson syndrome), and cardiac events including slow heart rhythm and heart attack.[8]
Overdose
safety citation needed The exact toxic dose in humans has not been established. The sole published overdose case involved ingestion of 2,000 mg (approximately 100 times the standard daily dose) by a 35-year-old woman.[9] She presented with unconsciousness, seizures, rapid heart rate, and high blood pressure. Treatment included intravenous diazepam for seizures and six cycles of plasmapheresis, and she made a full recovery.
No specific antidote for memantine overdose exists. Management follows standard NMDA antagonist overdose protocols: benzodiazepines for seizures, supportive care, and plasmapheresis in severe cases.[9]
Supratherapeutic dose gap
safety citation needed No controlled human safety data exist for memantine doses above 20 mg. The recreational dose range documented in community reports falls entirely within this evidence gap. Dose-response toxicity between the therapeutic ceiling (20 mg/day) and the single documented overdose (2,000 mg) remains uncharacterized.
Psychological risks
At therapeutic doses, hallucinations, confusion, and aggressive behavior are documented side effects — though in Alzheimer's patients these may reflect underlying disease rather than direct drug effects.[8]
At supratherapeutic doses, the primary psychological risk is duration. The 60–80 hour half-life means dissociative states persist for one to three days at doses needed for significant effects. Users describe feeling "disconnected from reality" and fearing that normal cognition will not return.[6] No formal case series documenting acute psychological crises from recreational memantine use have been published.
Tolerance & Dependence
Tolerance to memantine's therapeutic effects has not been observed in trials lasting up to 28 weeks.[7] Tolerance to dissociative effects at supratherapeutic doses has not been formally studied. Cross-tolerance with other dissociatives is plausible via shared NMDA receptor antagonism but lacks direct evidence.
Memantine has low to negligible dependence potential. A netnographic analysis of 128 online forum threads found limited abuse liability, noting that memantine's slow onset and extremely long duration serve as intrinsic deterrents to compulsive use.[6] No clinical withdrawal has been documented. Memantine is unscheduled in all major jurisdictions, reflecting regulatory assessment of low abuse potential.
Drug Interactions
Pharmacokinetic
Urinary alkalinizers (sodium bicarbonate, antacids, carbonic anhydrase inhibitors): the most significant interaction. These reduce memantine's kidney clearance by approximately 80%, potentially converting a safe dose into a toxic one.[8]
Urinary acidifiers (ammonium chloride): may increase clearance and reduce drug effect.
Hydrochlorothiazide: potential interaction via shared kidney excretion pathways.[8]
Memantine's negligible liver metabolism effectively eliminates interactions with CYP enzyme inhibitors and inducers.[8][25]
Pharmacodynamic
Other NMDA antagonists (ketamine, dextromethorphan, amantadine, nitrous-oxide): additive NMDA blockade increases risk of confusion, dissociation, and psychosis.[8]
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine): pharmacodynamically complementary. The combination is clinically approved (Namzaric) but may increase adverse effect rates.[14]
Dopaminergic agents (L-DOPA): some enhancement of L-DOPA effects is possible via NMDA–dopamine circuit interaction.[11][1]
Contraindications
7 knownHypersensitivity to memantine or any formulation component is an absolute contraindication.[8]
Severe kidney impairment roughly doubles blood levels and half-life. Memantine can be used with dose reduction, but this requires careful monitoring.
Concurrent use of other NMDA antagonists increases the risk of neuropsychiatric effects. FDA labeling advises caution.[8]
Conditions producing alkaline urine (kidney tubular acidosis, severe urinary tract infections, chronic antacid use) reduce memantine clearance by ~80% and can convert a tolerable dose into a dangerous one.[8]
Seizure disorders: seizures are documented in overdose and listed as a rare side effect. Caution is warranted in anyone with a lowered seizure threshold.[9][8]
Harm Reduction[edit]
Forms & Identification
Memantine circulates exclusively as pharmaceutical tablets, capsules, and oral solution — no clandestine production or unregulated powder forms have been documented. The primary identification concern is not adulteration but dose verification: tablets from different manufacturers and regions come in different strengths (5 mg, 10 mg, 14 mg, 21 mg, 28 mg), and generic formulations may differ in appearance. Confirm the exact strength marked on the tablet or packaging before dosing.
Because memantine is a legal prescription drug, reagent testing is less relevant than with unregulated substances. The key risk is not product substitution but pharmacokinetic unpredictability — urinary pH, kidney function, and individual variation produce wide differences in how intensely and how long the drug acts.
Guidelines
- Start low. Memantine's near-complete bioavailability and multiday duration mean dosing errors compound over days, not hours. Begin well below the intended target.
- Allow full onset time. Peak effects take 3–7 hours to develop. Do not redose before at least 8 hours have passed — stacking doses with a 60–80 hour half-life causes unpredictable accumulation.
- Monitor urinary pH. Antacids, sodium bicarbonate, and alkaline diets reduce memantine clearance by up to 80%. Avoid urinary alkalinizers before or during use.
- Clear your schedule. Block at minimum 48 hours with no driving, heavy machinery, or responsibilities requiring full cognitive function.
- Hydrate and eat normally. Memantine does not typically suppress appetite, but the multiday timeline makes sustained self-care essential.
- Do not use with impaired kidney function. Reduced clearance roughly doubles blood levels and extends the already long duration.
Set & Setting
Memantine's defining practical challenge is duration. At supratherapeutic doses, effects persist for one to three days — this is not an evening experience but a multiday commitment. Setting must account for obligations, driving, and cognitive demands across this entire window.
A familiar, comfortable environment with access to food, water, and sleep space is essential. The clear-headed character of memantine dissociation can create a false sense of normalcy; cognitive impairment may be deeper than it feels. A sober companion who understands the timeline is strongly recommended for first experiences.
Aftercare & integration. The multiday duration of memantine at supratherapeutic doses means the boundary between "experience" and "aftercare" is blurred. Residual cognitive blunting and emotional flatness may persist for two to four days after peak effects resolve.
During this period, prioritize sleep, regular meals, and low-demand activities. Avoid making significant decisions until baseline cognition clearly returns. Journaling the experience — both during and after — helps separate drug-state insights from residual dissociative thinking. If depersonalization or a sense of unreality persists beyond one week, consult a healthcare provider.
Recovery & Support
Memantine dependence is rare, but any pattern of escalating recreational use — particularly with a drug that requires multiday commitments per session — warrants honest self-assessment. If use is driven by a desire to escape emotional pain or cognitive distress, addressing the underlying need with professional support is more effective than repeated dissociative experiences.
Resources for dissociative-related concerns include SAMHSA's National Helpline (1-800-662-4357), local addiction services, and online harm reduction communities. If memantine was obtained via prescription diversion, discussing the pattern with a prescriber — while uncomfortable — reduces long-term risk.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Seizures or convulsions
- Unresponsiveness or loss of consciousness
- Severe confusion progressing to inability to communicate
- Tachycardia with chest pain or difficulty breathing
- Sustained high blood pressure (throbbing headache, visual disturbances)
Immediate steps:
- Call emergency services if any of the above signs are present.
- Place an unconscious person in the recovery position.
- Do not induce vomiting.
- Do not attempt to "walk off" seizures — protect the head, clear the area, time the seizure.
- Keep the person calm and in a quiet environment if conscious but severely confused.
What to tell the dispatcher: name the substance (memantine), the amount taken, when it was taken, and current symptoms. Note the extremely long half-life (60–80 hours) — effects will not resolve quickly. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific antidote exists. Hospital treatment may include benzodiazepines for seizures and plasmapheresis for severe overdose.
Legal Status[edit]
Memantine is a prescription-only pharmaceutical approved for moderate-to-severe Alzheimer's disease in all major jurisdictions. It is not classified as a controlled substance under any national drug scheduling framework — consistent with its low abuse potential, unfavorable recreational pharmacokinetics, and absence of documented dependence syndrome.[6]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Prescription drug (not scheduled DEA I–V) | FDA-approved October 2003 (NDA 21-627, Namenda). Off-label prescribing legal. 145th most prescribed drug in 2023 (>3 million prescriptions)[3] |
| European Union | Prescription-only medicine | EMA-approved since 2002 for moderate-to-severe AD. Not scheduled as a controlled substance in any EU member state[2] |
| United Kingdom | Prescription-only medicine (POM) | Not scheduled under the Misuse of Drugs Act 1971. Available on NHS for Alzheimer's diseasecitation needed |
| Canada | Prescription-only | Licensed for moderate-to-severe AD. Not a controlled substance. Provincial reimbursement variescitation needed |
| Australia | Schedule 4 (Prescription Only Medicine) | TGA-listed. Not scheduled as a controlled drugcitation needed |
Memantine is not detected by standard immunoassay drug screening panels. Identification requires gas chromatography–mass spectrometry (GC-MS) or liquid chromatography–tandem mass spectrometry (LC-MS/MS).citation needed
Frequently asked questions
What is Memantine?
Memantine is a synthetic adamantane dissociative and NMDA receptor antagonist approved for moderate-to-severe Alzheimer's disease. First synthesized by Eli Lilly in the 1960s, it is distinguished by near-complete oral bioavailability and a 60–80 hour elimination half-life.
How long does Memantine last?
Total duration by route of administration — Oral: 18 – 36 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Memantine?
Psychedex publishes a dosage table for Memantine on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Memantine?
The highest-severity documented interactions for Memantine: GHB, GBL (Lethal), Anticholinergics (Dangerous), Antihistamines (Dangerous), Antipsychotics (Dangerous), Benzodiazepines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Memantine addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Memantine: tolerance builds none; cross-tolerance develops with ketamine, dextromethorphan, PCP, nitrous oxide, MXE. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcdKilpatrick GJ, Tilbrook GS (2002) Memantine. Merz. — Current Opinion in Investigational Drugs PMID:12090556
- [3] ^abcdMöbius HJ, Stöffler A, Graham SM (2004) Memantine hydrochloride: pharmacological and clinical profile — Drugs of Today PMID:15510240
- [4] ^Sani G, Serra G, Kotzalidis GD, et al. (2012) The role of memantine in the treatment of psychiatric disorders other than the dementias — CNS Drugs doi:10.2165/11634390-000000000-00000
- [5] ^Joshi G, Gönenc A, DiSalvo M, Faraone SV, et al. (2025) Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder: A Randomized Clinical Trial — JAMA Network Open doi:10.1001/jamanetworkopen.2025.34927
- [6]
references
- [1]
- [2] ^abcdKilpatrick GJ, Tilbrook GS (2002) Memantine. Merz. — Current Opinion in Investigational Drugs PMID:12090556
- [3] ^abcdMöbius HJ, Stöffler A, Graham SM (2004) Memantine hydrochloride: pharmacological and clinical profile — Drugs of Today PMID:15510240
- [4] ^Sani G, Serra G, Kotzalidis GD, et al. (2012) The role of memantine in the treatment of psychiatric disorders other than the dementias — CNS Drugs doi:10.2165/11634390-000000000-00000
- [5] ^Joshi G, Gönenc A, DiSalvo M, Faraone SV, et al. (2025) Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder: A Randomized Clinical Trial — JAMA Network Open doi:10.1001/jamanetworkopen.2025.34927
- [6]